SELLAS Life Sciences Group, Inc.
SLSHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company carries a $1.73B market cap, placing it firmly in the small-cap category. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Cap
$1.73B
Beta
2.24
P/E (TTM)
—
P/E (Fwd)
-62.07
EPS (TTM)
$-0.23
EPS (Fwd)
$-0.15
ROE
-43.6%
ROA
-25.4%
Cash
$107.1M
Total Debt
$871,000
Free CF
-$17.7M
52W Change
489.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $107.1M in cash comfortably exceeding the $871K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$17.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -43.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.0M (2022) to $0 (2025), a 100% decline worth watching.
SELLAS Life Sciences Group, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, SLS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SLS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.